1. Home
  2. For Physicians
  3. Current Cancer Clinical Trials at Emory Decatur Hospital

Current Cancer Clinical Trials at Emory Decatur Hospital

Emory Decatur Hospital is currently participating in the following cancer clinical trials. If you see an open trial below that you're interested in, please contact the Clinical Trials staff at 404.501.5701 or email us at clinicaltrials@dekalbmedical.org.

NCORP DCP-001

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP). A clinical trial screening tool protocol has been developed to facilitate the formulation of research questions; particularly those evaluating factors related to populations that are underrepresented in clinical trials, and address cancer care disparities.

NCORP DCP-001: https://www.georgiacancerinfo.org/images/public/embedded/DCP001Protocol.pdf

BREAST CANCER

AbbVie M12-914:

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Study Abstract: http://clinicaltrials.gov/ct2/show/NCT02163694?term=NCT02163694&rank=1

Eligibility Criteria: Click here for Eligibility Criteria.

Schema: Click here for Schema.

ALLIANCE A011106:

The use of Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Study Abstract: http://www.cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=753769

Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionTypeCode=EC§ionID=33654

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=33656

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionTypeCode=PFS§ionId=33658

BRAG-ONC TISSUE

The Biorepository (Tumor Tissue and Serum Repository or Tumor Bank) was established to provide a centralized service for biospecimen procurement and distribution, to support basic and translational research.

The repository is collecting and storing specimens under standardized conditions, with accompanying clinical and demographic information. The repository is supported by a web-accessible database for inventory management and annotation, and a long term storage facility with back-ups for cryo-preservation of biospecimens.

BRAG-ONC TISSUE: http://www.augusta.edu/mcg/pathology/biorepository/

NSABP B-43:

A trial for breast patients with Her-2-positive DCIS. This is a trial looking at whether there is better disease free survival in patients who receive 2 doses of Herceptin along with their radiation therapy for DCIS.

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT00769379?term=NSABP+B-43&rank=1

Eligibility Criteria:https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-43/B43_Eligibility_Checklist.pdf

Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-43/B-43_Schema.pdf

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/nsabp/nsabp-b-43/NSABP_B43_PFS_010612.pdf

NSABP B-47:

A trial for women who have a low percentage of Her-2 overexpression in their breast cancer. This trial is seeking to discover whether these women will benefit from the addition of Herceptin to their course of therapy.

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT01275677

Eligibility Criteria:https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-47/B47_EligibilityChecklist_121311.pdf

Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-47/B47_Schema_121311.pdf

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/nsabp/nsabp-b-47/NSABP_B47_PFS_121311.pdf

NSAP B-51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

Eligibility Criteria:https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/nsabp/nsabp-b-51/B51_EligibilityCriteria_011113.pdf

Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/nsabp/nsabp-b-51/B51_Schema_011113.pdf

NSABP B-52

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT02003209

Eligibility Criteria:https://www.ctsu.org/readfile.aspx?sectionTypeCode=EC§ionID=135012

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=135014

S0812:  Temporarily closed to accrual

This is a breast cancer prevention study that evaluates the effects of high dose vitamin D in pre-menopausal women who are at high risk for developing breast cancer.

S1007:

This is a clinical study for breast cancer patients who have 1-3 positive lymph nodes and a low risk of cancer recurrence. This trial is seeking to better understand if patients benefit from receiving chemotherapy in conjunction with standard endocrine therapy.

SWOG S1207:

Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT01674140

Eligibility Criteria:https://www.ctsu.org/readfile.aspx?sectionid=33394

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=30775

ENDOMETRIAL CANCER

GOG 0258:

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT00942357

Eligibility Criteria: Click here for Eligibility Criteria.

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=16739

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionTypeCode=PFS§ionId=19380

GOG 0275:

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT01822496

Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=29532

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=29531

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionTypeCode=PFS§ionId=29533

GOG 0277:

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) v. Observation for Uterus-Limited, High Grade Uterine  Leiomyosarcoma

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT01533207

Eligibility Criteria: Click here for Eligibility Criteria.

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=29337

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionTypeCode=PFS§ionId=29339

GENETICS

City of Hope Genetic Registry:

Patients and their families will be given the unique opportunity to take part in a confidential registry and biologic repository to help define the underlying predisposition to cancer. The study will help to answer questions about whether cancers may have a genetic or environmental cause (or both) and ultimately to learn more about susceptibility to cancer.

https://www.cityofhope.org/education/health-professional-education/cancer-genetics-education-program/intensive-course-in-cancer-risk-assessment-overview/ccg-community-of-practice

LUNG CANCER

ALCHEMIST E4512

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.

ALCHEMIST E4512: https://clinicaltrials.gov/ct2/show/NCT02201992

ECOG EA5152

This partially randomized phase II trial studies how well nivolumab, cabozantinib s-malate, and ipilimumab work in treating patients with stage IV non-small cell lung cancer that has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

EGOG EA5152: https://clinicaltrials.gov/ct2/show/NCT03468985

ECOG E5508:

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung Cancer.

Abstract: https://clinicaltrials.gov/ct2/show/NCT01107626

Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/ecog/e5508/E5508_Schema_081210.pdf

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/ecog/e5508/E5508_PFS_042712.pdf

RTOG 1306:

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT01822496

Eligibility Criteria: Click here for Eligibility Criteria.

Schema: https://www.ctsu.org/readfile.aspx?sectionTypeCode=SCHEMA§ionId=33165

SWOG S0819:

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).

Abstract: https://clinicaltrials.gov/ct2/show/NCT00946712

Eligibility Criteria: https://www.ctsu.org/readfile.aspx?sectionid=32&fname=protocols/swog/s0819/S0819_EligibilityCriteria_041512.pdf

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/swog/s0819/S0819_Schema_071509.pdf

SWOG S1400F

This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.

SWOG S1400F: https://clinicaltrials.gov/ct2/show/NCT03373760?term=swog+1400f&rank=1

SWOG S1400G

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

SWOG S1400G: https://clinicaltrials.gov/ct2/show/NCT03377556?term=swog+1400g&rank=1

MULTIPLE MYELOMA

ECOG E3A06:

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma.

Study Abstract: https://clinicaltrials.gov/ct2/show/NCT01169337

Schema: https://www.ctsu.org/readfile.aspx?sectionid=22&fname=protocols/ecog/e3a06/E3A06_Schema_Addend5_022012.pdf

Physician Fact Sheet: https://www.ctsu.org/readfile.aspx?sectionid=31&fname=protocols/ecog/e3a06/E3A06_PFS_072512.pdf

PROMIS and NBRST Tumor Registry Study:

These studies incorporate MammaPrint, a 70-gene array, of the participants’ breast tumor. Results are made available to the patient and her physician for discussion of further treatment options. The study is looking at whether the MammaPrint results will have a bearing on treatment options.

PROMIS: https://clinicaltrials.gov/ct2/show/NCT01617954

contact us

contact us online bill pay access my account
in the news
visit Press Releases